47 related articles for article (PubMed ID: 33312457)
1. Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices.
Dane A; Klein Gebbink AS; Brugma JD; Degrassat-Théas A; Hug MJ; Houlind MB; Paubel P; van der Kuy PHM; Uyl-de Groot CA
Appl Health Econ Health Policy; 2023 Nov; 21(6):905-914. PubMed ID: 37751107
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Generic Entry of Pharmaceuticals in Australia.
Jones AM; Serra-Sastre V; Kim H
Value Health Reg Issues; 2024 Jun; 43():101008. PubMed ID: 38925096
[TBL] [Abstract][Full Text] [Related]
3. Challenges of Incorporating Life Cycle Drug Pricing in Cost-Effectiveness Models: A Review of Methods and Modeling Suggestions.
Puls M; Horscroft J; Kearns B; Gladwell D; Church E; Johannesen K; Malcolm B; Borrill J
Value Health; 2024 Jul; 27(7):978-985. PubMed ID: 38513883
[TBL] [Abstract][Full Text] [Related]
4. Exploring the Evolution of Statin Pricing in Australia: Observations of Price Disclosure Effects on Pharmaceutical Benefits Scheme Expenditure.
Lee L; Kim H
Value Health Reg Issues; 2024 Mar; 40():27-34. PubMed ID: 37972431
[TBL] [Abstract][Full Text] [Related]
5. Global Barriers to Accessing Off-Patent Endocrine Therapies: A Renaissance of the Orphan Disease?
de Silva NL; Dissanayake H; Kalra S; Meeran K; Somasundaram NP; Jayasena CN
J Clin Endocrinol Metab; 2024 Apr; 109(5):e1379-e1388. PubMed ID: 37846800
[TBL] [Abstract][Full Text] [Related]
6. Variables affecting new drug prices in South Korea's pricing system.
Lee DY; Cho SH; Lee DH; Kang SJ; Lee JH
Front Pharmacol; 2024; 15():1370915. PubMed ID: 38783941
[No Abstract] [Full Text] [Related]
7. Price increase negotiations to address drug shortages in South Korea's national health insurance.
Yu SR; Lee JH
Front Pharmacol; 2023; 14():1307462. PubMed ID: 38111380
[TBL] [Abstract][Full Text] [Related]
8. Use of patent term extensions to restore regulatory time for medical devices in the United States.
Kuo CB; Richmond F
Expert Rev Med Devices; 2024 Jun; ():1-7. PubMed ID: 38831711
[TBL] [Abstract][Full Text] [Related]
9. ENTRY IN THE ADHD DRUGS MARKET: WELFARE IMPACT OF GENERICS AND ME-TOO'S.
Bokhari FA; Fournier GM
J Ind Econ; 2013 Jun; 61(2):339-392. PubMed ID: 25821242
[TBL] [Abstract][Full Text] [Related]
10. Concerns over expiry of some retained EU laws.
Vet Rec; 2023 Feb; 192(3):102. PubMed ID: 36734555
[No Abstract] [Full Text] [Related]
11. The Force of Expiration as a Sign in Anæsthesia [Abbreviated].
Morton HJ
Proc R Soc Med; 1945 Jun; 38(8):441-6. PubMed ID: 19993089
[No Abstract] [Full Text] [Related]
12. The Ether Patent.
N Am Medchir Rev; 1861 Jan; 5(1):183-184. PubMed ID: 38080154
[No Abstract] [Full Text] [Related]
13. GEFormerDTA: drug target affinity prediction based on transformer graph for early fusion.
Liu Y; Xing L; Zhang L; Cai H; Guo M
Sci Rep; 2024 Mar; 14(1):7416. PubMed ID: 38548825
[TBL] [Abstract][Full Text] [Related]
14. Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran.
Fens T; de Jong L; Kappelhoff B; Boersma C; Postma MJ
J Mark Access Health Policy; 2023; 11(1):2247719. PubMed ID: 37675057
[No Abstract] [Full Text] [Related]
15. TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.
Mermelstein S; Stevens H
Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056944
[TBL] [Abstract][Full Text] [Related]
16. The impact of patent expiry on drug prices: insights from the Dutch market.
van der Schans S; Vondeling GT; Cao Q; van der Pol S; Visser S; Postma MJ; Rozenbaum MH
J Mark Access Health Policy; 2020 Dec; 9(1):1849984. PubMed ID: 33312457
[No Abstract] [Full Text] [Related]
17. The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review.
Vondeling GT; Cao Q; Postma MJ; Rozenbaum MH
Appl Health Econ Health Policy; 2018 Oct; 16(5):653-660. PubMed ID: 30019138
[TBL] [Abstract][Full Text] [Related]
18. Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility.
Lee SM; Kim HJ; Suh D; Joung KI; Kim ES; Back HJ; Kwon JY; Park MJ; Suh DC
BMC Health Serv Res; 2021 Feb; 21(1):126. PubMed ID: 33549099
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
